BriaCell Therapeutics Corp. BCTXF Archives - Page 4 of 6

FridayDec 21, 2018 9:45 am

BriaCell Therapeutics Corp.’s (OTCQB: BCTXF) (TSX.V: BCT) Immunotherapy for Advanced Breast Cancer Patients Showing Promising Results

Confirmation of positive proof-of-concept with lead cancer drug candidate Bria-IMT as monotherapy demonstrates promising anti-tumor activity Off-the-shelf immunotherapies provide customized, cost effective treatment options Positive efficacy data with Bria-IMT was presented at a major breast cancer conference, the 2018 San Antonio Breast Cancer Symposium BriaCell Therapeutics Corp.’s poster presentation at 2018 San Antonio Breast Cancer Symposium now available for public review Global cancer immunotherapy market projected to be worth over $119 billion by 2021 Cancer patients facing limited therapeutic options are the focus for a team of scientists and clinicians at BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a clinical-stage…

WednesdayDec 19, 2018 2:57 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Presents Clinical Data from Ongoing Bria-IMT Trial at SABCS

Biotechnology company BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) recently presented data from its ongoing trial during the San Antonio Breast Cancer Symposium (“SABCS”), one of the largest breast cancer conferences in the world. An article discussing the company reads, “The December 6 conference poster session presentation showed safety and efficacy results of BriaCell’s phase I/IIa targeted immunotherapy trial in patients with advanced breast cancer, as well as the early safety data of the combination study of Bria-IMT™ with KEYTRUDA®. KEYTRUDA® targets protein PD-1, which can block immune system cells from fighting off tumor cells. KEYTRUDA® attempts to “release the brakes”…

MondayDec 17, 2018 9:30 am

BriaCell Therapeutics Corp.’s (OTCQB: BCTXF) (TSX.V: BCT) Breast Cancer Treatment Confirms Positive Anti-Tumor Activity

The safety of a novel combined advanced breast cancer treatment has proven to be excellent, BriaCell announced at a major breast cancer conference The monotherapy (i.e. drug on its own) clinical trial showed positive anti-tumor activity in patients with advanced breast cancer and metastases Further information about the efficiency of the Bria-IMT/KEYTRUDA combined treatment will be provided in the first quarter of 2019 Initial data from a combination study of Bria-IMT and KEYTRUDA (pembrolizumab) demonstrated an excellent safety profile, BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) announced at the 2018 San Antonio Breast Cancer Symposium (http://ibn.fm/ehRA0). During the conference, the…

ThursdayDec 13, 2018 2:58 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Creating Personalized Immunotherapy to Target the Most Common Cancer Affecting Women

Biotechnology company BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) is working to develop a novel, personalized immunotherapy treatment for patients with advanced breast cancer. A recent article further discussing BriaCell reads, “Improving the efficacy, safety and cost of care for those who are annually diagnosed with breast cancer continues to be at the forefront of medical research. An estimated 266,120 new cases of breast cancer are projected to be diagnosed in U.S. women during 2018, according to the National Cancer Institute (NCI) (http://ibn.fm/cUSKe). Female breast cancer represents 15.3 percent of all new cancer cases in the U.S., with nearly 41,000 women…

WednesdayDec 12, 2018 11:24 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Shares the Gift of Good News for Breast Cancer Patients at World’s Largest Breast Cancer Conference

Breast cancer is the leading cancer diagnosed in women, with more than two million new cases diagnosed this year BriaCell Therapeutics advancing prospects of its trademarked Bria-IMT immunotherapy treatment for breast cancer in phase I/IIa trial Company presented data from ongoing trial during San Antonio Breast Cancer Symposium, one of the largest breast cancer conferences in the world The holidays can be a particularly poignant time for receiving a cancer diagnosis as all of society celebrates a season of cheer and shares goodwill with each other, but the San Antonio Breast Cancer Symposium (SABCS), one of the largest breast cancer…

ThursdayDec 06, 2018 10:32 am

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Presents Initial Data from Bria-IMT Combination Study at Major Breast Cancer Conference

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatment options for cancer, this morning announced the presentation of initial safety data from the combination study of its lead candidate, Bria-IMT, with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)] and confirmation of positive proof of concept data on Bria-IMT for advanced breast cancer at the 2018 San Antonio Breast Cancer Symposium. “I am very excited about our data continuing to show robust biological activity of Bria-IMT™ in advanced breast cancer,” Dr. Bill Williams, president and CEO of BriaCell, stated in the news release.…

TuesdayDec 04, 2018 2:46 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advances Clinical Program Throughout 2018

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focusing its efforts on immuno-oncology through the development of targeted, safe treatment options for cancer, has been working diligently to advance its clinical program. A recent article discussing the company reads, “The company attained crucial safety and efficacy data via its clinical trials, and it also achieved proof of concept. The phase I/IIa study of its proof of concept clinical trial in advanced breast cancer achieved sustained tumor shrinkage at various sites in several patients. These results confirm the data collected through two previous trials, demonstrating the promising effect of the…

FridayNov 30, 2018 11:43 am

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Developing Targeted, Safe Cancer Treatment Options

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) is a biotechnology company focusing its efforts on immuno-oncology through the development of targeted, safe treatment options for cancer. A recent article discussing the company reads, “Currently, BriaCell Therapeutics has two major programs – Bria-IMT and Bria-OTS. Bria-IMT is currently in the clinic, while Bria-OTS is in the process of development, Williams said. Previous clinical testing of Bria-IMT has returned promising results. In a clinical trial for the treatment of advanced breast cancer, Bria-IMT contributed to tumor shrinkage in multiple sites (in patients with metastases). Through additional patient testing, the original observations were confirmed.”…

ThursdayNov 29, 2018 11:39 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) to Present Key Updates of Immuno-Oncology Tech at 2018 San Antonio Breast Cancer Symposium

BriaCell Therapeutics Corp. is working to develop the first off-the-shelf personalized immunotherapy for advanced breast cancer Clinical data reveals an excellent safety profile and potent anti-tumor activity for Bria-IMT in advanced breast cancer patients Combination study using Bria-IMT with Merck & Co., Inc.’s KEYTRUDA (pembrolizumab) in advanced breast cancer patients is ongoing Symposium covers the latest research on experimental biology, etiology, prevention, diagnosis and treatment of breast cancer and premalignant breast disease International audience from over 90 countries includes researchers, health professionals, physicians, oncologists and those with a special interest in breast cancer An immuno-oncology focused biotechnology company, BriaCell Therapeutics…

MondayNov 19, 2018 10:50 am

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) to Present Bria-IMT Clinical Data at San Antonio Breast Cancer Symposium

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatment options for cancer, this morning announced that its Bria-IMT will be featured in a poster session during this year’s San Antonio Breast Cancer Symposium (“SABCS”), to be held December 4-8, 2018, in San Antonio, Texas. The poster highlights data on Bria-IMT’s use as a monotherapy demonstrating positive proof-of-concept, as well as an initial safety and tolerability assessment for its use in combination with pembrolizumab [KEYTRUDA - manufactured by Merck & Co., Inc. (NYSE: MRK)] for advanced breast cancer. Thomas Jefferson University assistant professor of medical oncology…

Site Search

Company Search

Tag: BriaCell Therapeutics Corp. BCTXF